Production (Stage)
OptimizeRx Corporation
OPRX
$11.65
-$0.44-3.64%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 21.93M | 32.32M | 21.31M | 18.81M | 19.69M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.93M | 32.32M | 21.31M | 18.81M | 19.69M |
| Cost of Revenue | 8.58M | 10.29M | 7.86M | 7.11M | 7.49M |
| Gross Profit | 13.34M | 22.02M | 13.45M | 11.70M | 12.20M |
| SG&A Expenses | 14.36M | 17.30M | 13.43M | 14.38M | 16.17M |
| Depreciation & Amortization | 1.09M | 1.09M | 1.10M | 1.07M | 1.07M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.04M | 28.68M | 22.38M | 22.56M | 24.72M |
| Operating Income | -2.11M | 3.63M | -1.07M | -3.75M | -5.03M |
| Income Before Tax | -3.28M | 2.21M | -9.94M | -5.10M | -6.56M |
| Income Tax Expenses | -1.09M | 2.29M | -817.00K | -1.09M | 344.00K |
| Earnings from Continuing Operations | -2.20M | -78.00K | -9.12M | -4.01M | -6.90M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.20M | -78.00K | -9.12M | -4.01M | -6.90M |
| EBIT | -2.11M | 3.63M | -1.07M | -3.75M | -5.03M |
| EBITDA | -1.17M | 5.14M | -132.00K | -2.81M | -4.08M |
| EPS Basic | -0.12 | 0.00 | -0.50 | -0.22 | -0.38 |
| Normalized Basic EPS | -0.11 | 0.07 | -0.08 | -0.17 | -0.23 |
| EPS Diluted | -0.12 | 0.00 | -0.50 | -0.22 | -0.38 |
| Normalized Diluted EPS | -0.11 | 0.07 | -0.08 | -0.17 | -0.23 |
| Average Basic Shares Outstanding | 18.47M | 18.42M | 18.32M | 18.26M | 18.17M |
| Average Diluted Shares Outstanding | 18.47M | 18.42M | 18.32M | 18.26M | 18.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |